Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis

The application of allogeneic hematopoietic cell transplantation (allo-HCT) in non-Hodgkin lymphoma (NHL) patients ≥65 years in the United States is limited by lack of Medicare coverage for this indication. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Shah, Nirav N., Ahn, Kwang Woo, Litovich, Carlos, Fenske, Timothy S., Ahmed, Sairah, Battiwalla, Minoo, Bejanyan, Nelli, Dahi, Parastoo B., Bolaños-Meade, Javier, Chen, Andy I., Ciurea, Stefan O., Bachanova, Veronika, DeFilipp, Zachariah, Epperla, Narendranath, Farhadfar, Nosha, Herrera, Alex F., Haverkos, Bradley M., Holmberg, Leona, Hossain, Nasheed M., Kharfan-Dabaja, Mohamed A., Kenkre, Vaishalee P., Lazarus, Hillard M., Murthy, Hemant S., Nishihori, Taiga, Rezvani, Andrew R., D’Souza, Anita, Savani, Bipin N., Ulrickson, Matthew L., Waller, Edmund K., Sureda, Anna, Smith, Sonali M., Hamadani, Mehdi
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2018
Matèries:
Transplantation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5916010/
https://ncbi.nlm.nih.gov/pubmed/29685953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018018531
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars